News

An 81-year-old man with junctional epidermolysis bullosa (JEB) has lived with recurrent blistering since childhood and developed multiple cancers over his lifetime, including skin cancers and urothelial carcinoma, a rare cancer of the urethra, a case study reports. Of the multiple skin cancers, most of them were squamous cell…

People with recessive dystrophic epidermolysis bullosa (RDEB) often experience a profound loss of nerve cells in the front of the eye, accompanied by increased numbers of inflammatory immune cells, a study found, suggesting that treatments to promote the health of these nerve cells and reduce eye inflammation may be…

What began as a few friends jumping into icy Massachusetts waters to support a neighbor has surged into a global movement, with the 9th annual Plunge for Elodie set to raise millions for epidermolysis bullosa (EB) research this spring. Running from March through May, the fundraiser has…

Long-term treatment with dupilumab, an injection therapy approved for certain inflammatory conditions, reduces disease severity, promotes wound healing, and eases itch among people with different subtypes of dystrophic epidermolysis bullosa (DEB), including severe DEB. In their real-world study, researchers also reported that DEB patients treated with dupilumab experienced sustained…

A noninvasive ultrasound technique successfully “saw” through the skin of a teenager with severe recessive dystrophic epidermolysis bullosa (RDEB), detecting hidden inflammation and scarring without causing the patient any pain. According to a new case report, high-frequency ultrasound (HFUS) allowed doctors to map disease activity beneath the skin surface…

Inmune Bio plans to submit applications this year seeking regulatory approval in the U.K., the U.S., and the European Union of CORDStrom, its experimental stem cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Inmune announced in a press release that it has formally submitted a pre-submission package…

Low levels of zinc — an essential mineral that supports wound healing — in people with recessive dystrophic epidermolysis bullosa (RDEB) are linked to worse disease, poorer nutritional status, and a higher risk of body-wide complications among those with the rare skin condition, a new study in Spain has…

Selumetinib, a drug that’s approved to treat certain types of neurological tumors, may be an effective treatment for skin cancers in people with recessive dystrophic epidermolysis bullosa (RDEB), according to a new study. Researchers found that selumetinib treatment killed cancer cells in dish-based tests, while experiments in mouse models…

Women with epidermolysis bullosa (EB) generally do not experience a worsening of disease symptoms during pregnancy — in fact, some expectant mothers with EB, particularly those with more severe disease, report that symptoms such as itching and blistering ease during pregnancy. Those are the findings of a new study…

TCP-25 gel is well-tolerated by individuals with recessive dystrophic epidermolysis bullosa (RDEB) and may effectively accelerate wound healing, according to a Phase 1 trial. The Phase 1 trial (NCT05378997) compared TCP-25 administered in conjunction with standard care to standard care alone over…

A new mesh-free dressing developed using lipidocolloid technology (TLC) promotes the healing of various types of skin wounds, including those associated with fragile skin caused by epidermolysis bullosa (EB). That’s according to data from the HEAL clinical trial (NCT03640871), which evaluated the new dressing in 78…

Doubling the standard dose of the gene therapy Vyjuvek (beremagene geperpavec) successfully healed widespread wounds in a woman with recessive dystrophic epidermolysis bullosa (RDEB) without causing side effects, a new case report shows. While the topical gel is already approved in the U.S. to treat the disease, the…